KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPensionProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovoCure (NVCR) Short-term Investments (2016 - 2025)

NovoCure (NVCR) has disclosed Short-term Investments for 12 consecutive years, with $354.1 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 55.52% to $354.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $354.1 million through Dec 2025, down 55.52% year-over-year, with the annual reading at $354.1 million for FY2025, 55.52% down from the prior year.
  • Short-term Investments hit $354.1 million in Q4 2025 for NovoCure, up from $2.5 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $854.1 million in Q4 2022 to a low of $676000.0 in Q1 2023.
  • Historically, Short-term Investments has averaged $378.3 million across 5 years, with a median of $385.3 million in 2024.
  • Biggest five-year swings in Short-term Investments: crashed 99.91% in 2023 and later skyrocketed 61495.27% in 2024.
  • Year by year, Short-term Investments stood at $728.9 million in 2021, then grew by 17.18% to $854.1 million in 2022, then tumbled by 99.8% to $1.7 million in 2023, then soared by 45574.47% to $796.1 million in 2024, then crashed by 55.52% to $354.1 million in 2025.
  • Business Quant data shows Short-term Investments for NVCR at $354.1 million in Q4 2025, $2.5 million in Q3 2025, and $761.9 million in Q2 2025.